Somatic mutations in HRAS have been found to be associated with bladder cancer, thyroid carcinoma, salivary duct carcinoma, epithelial-myoepithelial carcinoma, and kidney cancers (25, 26). This evidence concerns the gene HRAS and epithelial-myoepithelial carcinoma.